Stock DNA
Pharmaceuticals & Biotechnology
CNY 19,641 Million (Large Cap)
72.00
NA
0.42%
0.32
6.74%
3.36
Revenue and Profits:
Net Sales:
986 Million
(Quarterly Results - Sep 2025)
Net Profit:
172 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.57%
0%
-13.57%
6 Months
-31.77%
0%
-31.77%
1 Year
-20.18%
0%
-20.18%
2 Years
19.8%
0%
19.8%
3 Years
-25.32%
0%
-25.32%
4 Years
-24.24%
0%
-24.24%
5 Years
-64.39%
0%
-64.39%
Betta Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
4.42%
EBIT to Interest (avg)
9.58
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.36
Tax Ratio
5.06%
Dividend Payout Ratio
20.68%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.85%
ROE (avg)
7.69%
Valuation key factors
Factor
Value
P/E Ratio
72
Industry P/E
Price to Book Value
4.95
EV to EBIT
63.93
EV to EBITDA
31.49
EV to Capital Employed
3.99
EV to Sales
9.54
PEG Ratio
NA
Dividend Yield
0.30%
ROCE (Latest)
6.24%
ROE (Latest)
6.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
985.90
813.90
21.13%
Operating Profit (PBDIT) excl Other Income
198.60
206.40
-3.78%
Interest
18.60
17.20
8.14%
Exceptional Items
28.00
0.60
4,566.67%
Consolidate Net Profit
172.30
35.20
389.49%
Operating Profit Margin (Excl OI)
201.50%
87.00%
11.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 21.13% vs -11.30% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 389.49% vs -63.14% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,884.00
2,442.10
18.10%
Operating Profit (PBDIT) excl Other Income
848.00
583.10
45.43%
Interest
46.90
56.50
-16.99%
Exceptional Items
-53.80
-4.90
-997.96%
Consolidate Net Profit
387.00
333.60
16.01%
Operating Profit Margin (Excl OI)
165.10%
114.50%
5.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 18.10% vs 3.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.01% vs 167.31% in Dec 2023
About Betta Pharmaceuticals Co., Ltd. 
Betta Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






